<?xml version='1.0' encoding='UTF-8' ?>
<Trials_downloaded_from_ICTRP>

    
  <Trial><Export_date>03/02/2024 23:28:02</Export_date>
    <Internal_Number>12776696
    </Internal_Number>
    <TrialID>NCT05678725
    </TrialID>
    <Last_Refreshed_on>23 January 2023
    </Last_Refreshed_on>
    <Public_title>Transcranial Direct/ Alternating Current Stimulation for Parkinson's Disease Treatment
    </Public_title>
    <Scientific_title>Comparison of Transcranial Direct Current Stimulation and Transcranial Alternating Current Stimulation Treatments in Improving the Motor and Cognitive Performance in Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Anhui Medical University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20221214
    </Date_registration3>
    <Date_registration>14/12/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05678725
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 15, 2022
    </Date_enrollement>
    <Target_size>80
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Junjie Bu, Professor
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Anhui Medical University
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  diagnosis of idiopathic PD according to the movement disorder society criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  right-handed&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  no clinically known hearing or vision impairment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  no history of epilepsy, dementia, other brain disorders apart from PD, severe internal&#x0D;&lt;br&gt;             organs disease, age-related frailty, etc.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  parkinsonism due to drugs, Cerebrovascular disease, encephalitis, poisoning, traumatic&#x0D;&lt;br&gt;             brain injury, etc.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Metal implants in the head (i.e., deep brain stimulator or aneurysm clips)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  severe somatic or psychiatric disorders that require medication or routinely&#x0D;&lt;br&gt;             monitoring&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  participated in other interventional studies within the past 3 months&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;tACS;tDCS
    </Condition>
    <Intervention>Device: tACS;Device: tDCS;Device: sham
    </Intervention>
    <Primary_outcome>the changes in UPDRS III;the changes in MoCA
    </Primary_outcome>
    <Secondary_outcome>simple reaction task;the changes in EEG power
    </Secondary_outcome>
    <Secondary_ID>tAtDComparePD
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:28:02</Export_date>
    <Internal_Number>12586850
    </Internal_Number>
    <TrialID>NCT05557786
    </TrialID>
    <Last_Refreshed_on>17 October 2022
    </Last_Refreshed_on>
    <Public_title>Treatment of Transcranial Alternating Current Stimulation(tACS)on Cerebellar Ataxia
    </Public_title>
    <Scientific_title>The Treatment of Transcranial Alternating Current Stimulation(tACS)on Patients With Cerebellar Ataxia: A Randomized, Triple-blind, Parallel-controlled Study
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>First Affiliated Hospital of Fujian Medical University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20220924
    </Date_registration3>
    <Date_registration>24/09/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05557786
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 1, 2022
    </Date_enrollement>
    <Target_size>164
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>China
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Shi-Rui Gan, MD, PhD;Shi-Rui Gan, MD.Phd
    </Contact_Lastname>
    <Contact_Email>ganshirui@fjmu.edu.cn;ganshirui@fjmu.edu.cn
    </Contact_Email>
    <Contact_Tel>0591-87982772;+8613850172725
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  for SCA3&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Patients with detectable clinical signs and confirmed genetic diagnosis with SCA3&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  SCA3 patients aged 18 - 80 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Patients or their family members have informed consent to the study and signed&#x0D;&lt;br&gt;                  relevant documents&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  The pre-study ataxia Assessment Score (SARA) ranged from 3 to 30&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  for MSA-C&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Aged 30-80 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Diagnosed as clinically determined (Established)MSA-C or clinically Probable&#x0D;&lt;br&gt;                  MSA-C according to the latest MSA diagnostic criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  No more than 4 years after diagnosis of MSA-C&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Able to walk independently or with assistance&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Have a life expectancy of at least 3 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Women of childbearing age with MSA need to use contraceptive measures&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Patients who have concomitant epilepsy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Patients with a serious cognitive disorder, behavioral disorder, or mental illness&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patients with a history of seizures, stroke, encephalitis, or other degenerative&#x0D;&lt;br&gt;             neurological diseases&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patients with a serious medical disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Patients who concomitantly suffer from severe renal impairment, convulsions,&#x0D;&lt;br&gt;                  stomach ulcers, or moderate or more severe liver disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               -  Patients with uncontrolled high blood pressure or diabetes&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. History of head injury or neurosurgical interventions.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. History of any metal in the head (outside the mouth).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Known history of any metallic particles in the eye, implanted cardiac pacemaker,&#x0D;&lt;br&gt;             implanted neurostimulators, surgical clips (above the shoulder line), or any medical&#x0D;&lt;br&gt;             pumps.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Patients who have taken other investigational products within 4 weeks before being&#x0D;&lt;br&gt;             enrolled in this clinical trial, or patients who are pregnant or breastfeeding.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Spinocerebellar Ataxia Type 3;Multiple System Atrophy-cerebellar Type
    </Condition>
    <Intervention>Device: Transcranial Alternating Current Stimulation
    </Intervention>
    <Primary_outcome>Changes in Ataxia symptoms (Scale for the Assessment and Rating of Ataxia (SARA));Changes of Clinical Evaluation from UMSARS (Unified Multiple System Atrophy Rating Scale) (only for MSA-C)
    </Primary_outcome>
    <Secondary_outcome>Changes in the International Cooperative Ataxia Rating Scale (ICARS) Score From Baseline;Changes in the Scale for the Assessment and Rating of Ataxia (SARA) Score From Baseline;Changes in the 9 Hole Peg Test (9HPT) Score From Baseline;Hand Grip Strength;Pittsburgh Sleep Quality Index (PSQI);Epworth score;Montreal Cognitive Assessment (MoCA);Mini-Mental State Examination (MMSE);Hamilton Anxiety Scale (HAMA);Hamilton Depression Scale (HAMD);Changes From Baseline in 5 Level EQ-5D (EQ-5D-5L);Multiple System Atrophy Quality of Life (MSA-QoL) Score;Spatiotemporal dynamic changes measured with electroencephalography (EEG);Changes from temporospatial parameters of gait;Changes in Neuroimage changes in Magnetic Resonance Imaging (MRI)
    </Secondary_outcome>
    <Secondary_ID>MRCTA, ECFAH of FMU[2022]399
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:28:02</Export_date>
    <Internal_Number>11897258
    </Internal_Number>
    <TrialID>NCT05220449
    </TrialID>
    <Last_Refreshed_on>7 February 2022
    </Last_Refreshed_on>
    <Public_title>Re-Orchestration of Interregional Oscillatory Activity to Promote Visual Recovery
    </Public_title>
    <Scientific_title>Individualized Brain Stimulation to Improve Functional Rehabilitation in Two Models of Sensorimotor Disorders: Stroke and Parkinson's Disease
    </Scientific_title>
    <Acronym>R4V
    </Acronym>
    <Primary_sponsor>Ecole Polytechnique Fédérale de Lausanne
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20211130
    </Date_registration3>
    <Date_registration>30/11/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05220449
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 1, 2017
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Single (Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Switzerland
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Estelle Raffin, PhD;Pauline Stehli, Msc
    </Contact_Lastname>
    <Contact_Email>estelle.raffin@epfl.ch;
    </Contact_Email>
    <Contact_Tel>0216955185;
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. the patient can consent for themselves;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. age 18+ years old;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. at least 7 days since diagnosis "stroke".&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patients should demonstrate a clear deficit in either simple or complex visual&#x0D;&lt;br&gt;             perception in portions of their visual field&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Diminished capacity to consent;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Known or suspected non-compliance, drug or alcohol abuse&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Inability to follow the procedures of the study, e.g., due to language problems,&#x0D;&lt;br&gt;             psychological disorders, dementia, etc. of the participant,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Non-compliance to the instructions of the experimenter or an inappropriate behavior&#x0D;&lt;br&gt;             hindering the normal progress of the experiment.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Previous enrolment into the current study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Exclusion criteria of MRI, tACS, TMS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Use of psychoactive medication&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Visual Impairment;Stroke;Parkinson Disease
    </Condition>
    <Intervention>Other: Cross-frequency dual-site tACS
    </Intervention>
    <Primary_outcome>Changes in visual field functions
    </Primary_outcome>
    <Secondary_outcome>Changes in motion discrimination and integration performances;Changes in inter-areal cross-frequency interaction;Changes in visual tracts integrity;Changes in functional connectivity within the broad visual network
    </Secondary_outcome>
    <Secondary_ID>2017-01761
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:28:02</Export_date>
    <Internal_Number>13645400
    </Internal_Number>
    <TrialID>DRKS00024035
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>The effects of gamma tACS on cortical excitability and movement in Parkinson patients compared to healthy controls
    </Public_title>
    <Scientific_title>The effects of gamma tACS on cortical excitability and movement in Parkinson patients compared to healthy controls - park GammatACS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
    </Scientific_title>
    <Primary_sponsor>Carl von Ossietzky Universität Oldenburg Fakultät VI - Medizin und Gesundheitswissenschaften Department für Humanmedizin
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210406
    </Date_registration3>
    <Date_registration>06/04/2021
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00024035
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>50 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>22/04/2021
    </Date_enrollement>
    <Target_size>24
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: Randomized controlled study; Masking: Blinded (masking used); Control: placebo; Assignment: factorial; Study design purpose: treatment 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Martina
    </Contact_Firstname>
    <Contact_Lastname>Bantel
    </Contact_Lastname>
    <Contact_Address>Heiligengeisthöfe 4
    </Contact_Address>
    <Contact_Email>neurologie@uol.de
    </Contact_Email>
    <Contact_Tel> +49 (0)441 798-4657
    </Contact_Tel>
    <Contact_Affiliation>Sekretariat der Universitätsklinik für NeurologieCarl von Ossietzky Universität Oldenburg
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Parkinson Patients:&#x0D;&lt;br&gt;a) diagnosed PD in a mild to moderate stage, equivalent UPDRS (part III) &lt; 35&#x0D;&lt;br&gt;b) Right-handedness &#x0D;&lt;br&gt;c) Age 50 -75 years&#x0D;&lt;br&gt;d) Fluency in German or English.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Healthy Subjects are recruited based on : b), c) and d)
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: For healthy subjects and PD patients:&#x0D;&lt;br&gt;a) Implanted neurostimulators, cochlear implants or general implanted metal in the cranium&#x0D;&lt;br&gt;b) Psychiatric disorders (i.e. schizophrenia, severe dementia)&#x0D;&lt;br&gt;c) Epilepsy&#x0D;&lt;br&gt;d) Use of contraindicated medication (i.e. neuroleptics, opioids)&#x0D;&lt;br&gt;e) Coffee or alcohol consumption prior to the experiment
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20 &lt;br&gt;G20.1;Parkinson disease;G20.1
    </Condition>
    <Intervention>Group 1: This study evaluates the effect of gamma tACS on movement and cortical excitability in Parkinson patients and healthy participants. Both groups undergo 2 sessions: in one session they will receive 20 min. of gamma tACS, whereas in the other session they will receive sham stimulation. Which session the participant will first be enrolled in is randomized.&lt;br&gt;&lt;br&gt;Arm 1= Parkinson patients (gamma tACS and Sham)&lt;br&gt;Group 2: Arm 2 = healthy participants (gamma tACS and sham)
    </Intervention>
    <Primary_outcome>The endpoint is the improvement of motor function after gamma tACS. Improve motor function will be assessed by the UPDRS, and changes in results in the Nine-hole- peg test and alternating finger tapping task.
    </Primary_outcome>
    <Secondary_outcome>The secondary endpoint is the change in reaction time after the execution of a motor task in the course of the experiment.
    </Secondary_outcome>
    <Source_Support>Carl von Ossietzky Universität OldenburgFakultät VI - Medizin und GesundheitswissenschaftenDepartment für Humanmedizin
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/04/2021
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>med.ethikkommission@uni-oldenburg.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Geschäftsstelle der medizinischen Ethikkommission, Fakultät VI Medizin und Gesundheitswissenschaften, Carl von Ossietzky Universität Oldenburg, Gebäude V04 (Raum 1-137)
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-441-7983109
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>med.ethikkommission@uni-oldenburg.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00024035#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:28:02</Export_date>
    <Internal_Number>10374067
    </Internal_Number>
    <TrialID>NCT04509349
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Alternating Current Stimulation for Essential Tremor
    </Public_title>
    <Scientific_title>Alternating Current Stimulation for Essential Tremor: a Pilot Study to Identify the Most Promising Strategy
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Calgary
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200720
    </Date_registration3>
    <Date_registration>20/07/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04509349
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 1, 2020
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Davide Martino, MD, PhD;Elaheh NosratMirshekarlou, MSc
    </Contact_Lastname>
    <Contact_Email>;elaheh.nosratmirshek@ucalgary.ca
    </Contact_Email>
    <Contact_Tel>;0014032106876
    </Contact_Tel>
    <Contact_Affiliation>Department of Clinical Neurosciences, University of Calgary;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants who meet Diagnostic and Statistical Manual of Mental Disorders criteria&#x0D;&lt;br&gt;             for ET (APA, DSM V).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  18 years of age or older.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants should be either un-medicated or on stable medication treatment for&#x0D;&lt;br&gt;             tremor for the previous 3 months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Psychiatric comorbidities should be clinically stable; treatment has not changed in&#x0D;&lt;br&gt;             the last 3 months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have a metal object/implant in their brain, skull, scalp, or neck.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have an implantable device (e.g., cardiac pacemaker).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have a diagnosis of epilepsy or cardiac disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have a history of traumatic brain injury, learning disability or dyslexia.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have a severe impediment in vision or hearing.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Essential Tremor
    </Condition>
    <Intervention>Device: transcranial Altering Current Stimulation;Device: Sham tACS
    </Intervention>
    <Primary_outcome>Essential Tremor Severity Change
    </Primary_outcome>
    <Secondary_ID>REB20-0889
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:28:02</Export_date>
    <Internal_Number>10339943
    </Internal_Number>
    <TrialID>NCT04065022
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>The Trans-cutaneous Effects on Physiological Tremor Entertainment During tACS
    </Public_title>
    <Scientific_title>The Trans-cutaneous Effects on Physiological Tremor Entertainment During tACS
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>KU Leuven
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190205
    </Date_registration3>
    <Date_registration>05/02/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04065022
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 20, 2017
    </Date_enrollement>
    <Target_size>22
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: Single (Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Belgium
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Above 18&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Signed informed consents&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of Epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Family history of Epilepsy&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Tremor, Limb
    </Condition>
    <Intervention>Device: tACS at tremor frequency
    </Intervention>
    <Primary_outcome>Change in tremor-stimulation phase entrainment- Session 1;Change in tremor-stimulation phase entrainment- Session 2;Change in tremor-stimulation phase entrainment- Session 3
    </Primary_outcome>
    <Secondary_outcome>Sensation rating;Sensation threshold
    </Secondary_outcome>
    <Secondary_ID>S57869-1
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:28:02</Export_date>
    <Internal_Number>13748460
    </Internal_Number>
    <TrialID>NL-OMON29165
    </TrialID>
    <Last_Refreshed_on>28 February 2024
    </Last_Refreshed_on>
    <Public_title>Tremor in Dystonia and Essential tremor.
    </Public_title>
    <Scientific_title>The cerebral mechanisms underlying dystonic and essential tremor: a multimodal network approach                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    </Scientific_title>
    <Primary_sponsor>Donders Institute for Brain, Cognition and Behaviour. Centre for Cognitive Neuroimaging.&#x0D;
Kapittelweg 29 6525 EN Nijmegen
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20171130
    </Date_registration3>
    <Date_registration>2017-11-30
    </Date_registration>
    <Source_Register>NL-OMON
    </Source_Register>
    <web_address>https://onderzoekmetmensen.nl/en/trial/29165
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>2017-12-01
    </Date_enrollement>
    <Target_size>32
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Non-randomized controlled trial, Single blinded (masking used), Active, Crossover
    </Study_design>
    <Phase/>
    <Contact_Firstname>Freek 
    </Contact_Firstname>
    <Contact_Lastname>Nieuwhof
    </Contact_Lastname>
    <Contact_Address/>
    <Contact_Email>freek.nieuwhof@radboudumc.nl
    </Contact_Email>
    <Contact_Tel/>
    <Contact_Affiliation/>
    <Inclusion_Criteria>Inclusion criteria: Essential tremor: &lt;br /&gt;&lt;br&gt;-Clinical diagnosis of essential tremor&lt;br /&gt;&lt;br&gt;-Postural tremor of both hands&lt;br /&gt;&lt;br&gt;-Onset of tremor before the age of 65&lt;br&gt;&lt;br&gt;Dystonic tremor:&lt;br&gt;-Clinical diagnosis of dystonic tremor&lt;br&gt;-Primary focal / segmental dystonia&lt;br&gt;-Presence of postural tremor of at least one arm (which may or may not be the dystonic limb)
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: -Neurological co-morbidity&lt;br /&gt;&lt;br&gt;-Moderate to severe head tremor (to avoid artifacts caused by extensive head motion during scanning)&lt;br /&gt;&lt;br&gt;-Cognitive dysfunction (clinical diagnosis of mild cognitive impairment or dementia)&lt;br /&gt;&lt;br&gt;-Considerable diagnostic doubt between essential and dystonic tremor (no consensus reached in team meetings neurologists or considerable doubt in medical record).&lt;br /&gt;&lt;br&gt;-Use of anti-tremor medication other than propranolol&lt;br /&gt;&lt;br&gt;-Any contraindications for MRI or transcranial stimulation (e.g. non compatible metal implants, epilepsy, active implants).
    </Exclusion_Criteria>
    <Condition>English: Dystonic tremor, Dystonia, Essential tremor, tacs&#x0D;
Dutch: Tremor bij Dystonie, Dystonie, Essentiële tremor, tacs, beven
    </Condition>
    <Intervention>Transcranial alternating current stimulation (tacs) over primary motor cortex and cerebellum at tremor frequency and phase locked to ongoing tremor (as measured with accelerometry). &lt;br /&gt;Stimulation during 20 blocks of 30s, at 18 degree phase difference increments around the phase circle (random ordering, phase difference between ongoing tremor and tacs).
    </Intervention>
    <Primary_outcome>1) phase specific tremor power suppression during M1 tacs, in ET vs DT&lt;br /&gt;&lt;br&gt;2) phase specific tremor power suppression during  Cerebellar tacs, in ET vs DT&lt;br /&gt;&lt;br&gt;3) Phase specific tremor related cerebral activity during cerebellar tacs, in ET vs DT 
    </Primary_outcome>
    <Secondary_outcome>-Tremor related cerebral activity and connectivity, compared between dystonic and essential tremor.&lt;br /&gt;&lt;br&gt;-GABA concentrations in GPi, cerebellum and primary motor cortex, compared between dystonic and essential tremor.&lt;br /&gt;&lt;br&gt;&lt;br&gt;
    </Secondary_outcome>
    <Secondary_ID>NL6686;NTR6856;NL60335.091.17 : HA2016-02-01
    </Secondary_ID>
    <Source_Support>Hersenstichting (Dutch brain foundation)
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>30/11/2017
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:28:02</Export_date>
    <Internal_Number>6695410
    </Internal_Number>
    <TrialID>NCT03337334
    </TrialID>
    <Last_Refreshed_on>16 December 2017
    </Last_Refreshed_on>
    <Public_title>Effects of High Amplitude and Focused tACS on Entraining Physiological Tremor
    </Public_title>
    <Scientific_title>Effects of High Amplitude and Focused tACS on Entraining Physiological Tremor
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Katholieke Universiteit Leuven
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20171101
    </Date_registration3>
    <Date_registration>01/11/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03337334
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 2016
    </Date_enrollement>
    <Target_size>23
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: Single (Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Above 18&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  signed informed written consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of Epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Family history of Epilepsy&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Above 18&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  signed informed written consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of Epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Family history of Epilepsy&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Above 18&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  signed informed written consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of Epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Family history of Epilepsy&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Above 18&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  signed informed written consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of Epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Family history of Epilepsy&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Tremor, Limb;Tremor, Limb;Tremor, Limb;Tremor, Limb
    </Condition>
    <Intervention>Device: tACS at tremor frequency;Device: tACS at tremor frequency;Device: tACS at tremor frequency;Device: tACS at tremor frequency
    </Intervention>
    <Primary_outcome>Tremor-stimulation phase entrainment;Tremor-stimulation phase entrainment;Tremor-stimulation phase entrainment
    </Primary_outcome>
    <Secondary_outcome>Phosphene rating;Phosphene threshold
    </Secondary_outcome>
    <Secondary_ID>S57869
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:28:02</Export_date>
    <Internal_Number>13728082
    </Internal_Number>
    <TrialID>NL-OMON45367
    </TrialID>
    <Last_Refreshed_on>28 February 2024
    </Last_Refreshed_on>
    <Public_title>Guiding personalized treatments for Parkinson*s tremor with individual neuroimaging * an exploratory study
    </Public_title>
    <Scientific_title>Guiding personalized treatments for Parkinson*s tremor with individual neuroimaging * an exploratory study - Tremor fingerprints in Parkinson's disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    </Scientific_title>
    <Primary_sponsor>Neurologie
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170503
    </Date_registration3>
    <Date_registration>2017-05-03
    </Date_registration>
    <Source_Register>NL-OMON
    </Source_Register>
    <web_address>https://onderzoekmetmensen.nl/en/trial/45367
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18
    </Inclusion_agemin>
    <Inclusion_agemax>64
    </Inclusion_agemax>
    <Inclusion_gender/>
    <Date_enrollement>2018-01-25
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Open (masking not used), Uncontrolled, Basic science
    </Study_design>
    <Phase>2
    </Phase>
    <Countries>The Netherlands
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address>Reinier Postlaan 4
    </Contact_Address>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Selecteer
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;p&gt;- Idiopathic Parkinson*s disease according to UK brain bank criteria. &lt;br&gt;- Presence of a clear resting tremor of at least one arm (UPDRS tremor-score &gt; 2). &lt;br&gt;&lt;/p&gt;&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;p&gt;- neuropsychiatric co-morbidity &lt;br&gt;- contraindications for MRI scanning (e.g. pacemaker, implanted metal parts, deep brain stimulation, claustrophobia) &lt;br&gt;- Severe head tremor or dyskinesias. &lt;br&gt;- Cognitive impairment (MMSE &lt; 26)&lt;/p&gt;&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;Parkinson's disease &lt;br&gt;tremor;10028037;Parkinson's disease;tremor
    </Condition>
    <Intervention>&lt;p&gt;The intervention involves TACS, which is a non-invasive, non-painful way of &lt;br&gt;stimulating underlying cortical brain tissue through electrodes applied to the &lt;br&gt;scalp. When applied rhythmically at the frequency of cortical oscillatory &lt;br&gt;activity, it can exert excitatory or inhibitory (depending on the phase) &lt;br&gt;effects on brain function. In this research, we will apply TACS over the motor &lt;br&gt;cortex contralateral to the tremulous hand, in the same frequency, and &lt;br&gt;phase-locked to, the ongoing tremor. There are three conditions: inhibitory &lt;br&gt;TACS (anti-phase), stimulating TACS (in-phase), and sham (no/fake stimulation). &lt;br&gt;TACS will be applied both outside and inside the MRI scanner, to test for the &lt;br&gt;effect on the tremor circuitry.&lt;/p&gt;&lt;br&gt;;fMRI;Parkinson;tDCS;tremor
    </Intervention>
    <Primary_outcome>&lt;p&gt;(1) Within-subjects reproducibility of tremor-related activity and connectivity&lt;br /&gt;&lt;br&gt;(*tremor fingerprint*; quantified using concurrent EMG-fMRI across two&lt;br /&gt;&lt;br&gt;different days); (2) Modulation of tremor-related activity and connectivity by&lt;br /&gt;&lt;br&gt;TACS (comparison of the three TACS conditions); (3) Modulation of tremor by&lt;br /&gt;&lt;br&gt;TACS (quantified using accelerometry), and its correlation with network&lt;br /&gt;&lt;br&gt;parameters derived from the tremor circuit (i.e. thalamo-cortical&lt;br /&gt;&lt;br&gt;connectivity). &lt;/p&gt;&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>&lt;p&gt;Not applicable. See Primary outcome measure.&lt;/p&gt;&#x0D;&lt;br&gt;
    </Secondary_outcome>
    <Secondary_ID>NL60572.091.17
    </Secondary_ID>
    <Source_Support>ZonMw (Off Road subsidie)
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>03/05/2017
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>07/09/2019
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:28:02</Export_date>
    <Internal_Number>13727991
    </Internal_Number>
    <TrialID>NL-OMON45276
    </TrialID>
    <Last_Refreshed_on>28 February 2024
    </Last_Refreshed_on>
    <Public_title>The cerebral mechanisms underlying dystonic and essential tremor: a multimodal network approach
    </Public_title>
    <Scientific_title>The cerebral mechanisms underlying dystonic and essential tremor: a multimodal network approach - Cerebral mechanisms in dystonic and essential tremor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
    </Scientific_title>
    <Primary_sponsor>Radboud Universitair Medisch Centrum
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170406
    </Date_registration3>
    <Date_registration>2017-04-06
    </Date_registration>
    <Source_Register>NL-OMON
    </Source_Register>
    <web_address>https://onderzoekmetmensen.nl/en/trial/45276
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18
    </Inclusion_agemin>
    <Inclusion_agemax>64
    </Inclusion_agemax>
    <Inclusion_gender/>
    <Date_enrollement>2017-10-20
    </Date_enrollement>
    <Target_size>32
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Open (masking not used), Uncontrolled, Basic science
    </Study_design>
    <Phase/>
    <Countries>The Netherlands
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname/>
    <Contact_Address>Reinier Postlaan 4
    </Contact_Address>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Radboud Universitair Medisch Centrum
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: &lt;p&gt;For essential tremor patients: &lt;br&gt;-Clinical diagnosis of essential tremor &lt;br&gt;-Postural tremor of both hands &lt;br&gt;-Onset of tremor before the age of 65 (to exclude pathophysiological heterogeneity caused by age-related tremor [15]);For dystonic tremor patients: &lt;br&gt;-Clinical diagnosis of dystonic tremor &lt;br&gt;-Primary focal / segmental dystonia &lt;br&gt;-Presence of postural tremor of at least one arm (which may or may not be the dystonic limb)&lt;/p&gt;&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;p&gt;-Neurological co-morbidity &lt;br&gt;-Moderate to severe head tremor (to avoid artifacts caused by extensive head motion during scanning) &lt;br&gt;-Cognitive dysfunction (clinical diagnosis of mild cognitive impairment or dementia) &lt;br&gt;-MRI or TACS contraindications &lt;br&gt;&lt;/p&gt;&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;dystonia;10028037;dystonia
    </Condition>
    <Intervention>&lt;p&gt;The intervention involves transcranial alternating current stimulation (TACS), &lt;br&gt;which is a non-invasive, non-painful way of stimulating underlying cortical &lt;br&gt;brain tissue through electrodes applied to the scalp. When applied rhythmically &lt;br&gt;at the frequency of cortical oscillatory activity, it can exert powerful &lt;br&gt;excitatory or inhibitory (depending on the phase) effects on brain function.&lt;/p&gt;&lt;br&gt;;Dystonia;Essential tremor;Neuroscience;Tremor
    </Intervention>
    <Primary_outcome>&lt;p&gt;We will use concurrent EMG-fMRI to localize and compare tremor-related activity&lt;br /&gt;&lt;br&gt;between both groups (outcome #1) - an approach we have previously validated in&lt;br /&gt;&lt;br&gt;Parkinson*s tremor. &lt;/p&gt;&lt;br&gt;
    </Primary_outcome>
    <Secondary_outcome>&lt;p&gt;Given the hypothesized role of inhibitory GABA-ergic circuits in both tremor&lt;br /&gt;&#x0D;&lt;br&gt;types, we will use 3T magnetic resonance spectroscopy to compare GABA&lt;br /&gt;&#x0D;&lt;br&gt;concentrations in the internal globus pallidus, cerebellum, and motor cortex&lt;br /&gt;&#x0D;&lt;br&gt;between both groups (outcome #2). Also, we use a non-invasive, adaptive and&lt;br /&gt;&#x0D;&lt;br&gt;controlled brain stimulation approach (transcranial alternating current&lt;br /&gt;&#x0D;&lt;br&gt;stimulation; TACS) to test for the effect of inhibiting the motor cortex and&lt;br /&gt;&#x0D;&lt;br&gt;cerebellum on tremor intensity (accelerometry) and, for the cerebellum, on&lt;br /&gt;&#x0D;&lt;br&gt;tremor-related activity (EMG-fMRI) and (outcome #3). Previous research has&lt;br /&gt;&#x0D;&lt;br&gt;shown powerful modulatory influences of TACS on both Parkinson*s tremor and ET. &lt;/p&gt;&#x0D;&lt;br&gt;
    </Secondary_outcome>
    <Secondary_ID>NL60335.091.17
    </Secondary_ID>
    <Source_Support>Hersenstichting
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>06/04/2017
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:28:02</Export_date>
    <Internal_Number>10920903
    </Internal_Number>
    <TrialID>NCT03221413
    </TrialID>
    <Last_Refreshed_on>10 May 2021
    </Last_Refreshed_on>
    <Public_title>Transcranial Alternating Current for Oscillopathies
    </Public_title>
    <Scientific_title>A Translational, Multimodal Approach to Implementing Non-invasive Paradigms for the Treatment of Oscillopathies
    </Scientific_title>
    <Acronym>tACS_EEG
    </Acronym>
    <Primary_sponsor>University of Padova
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20160211
    </Date_registration3>
    <Date_registration>11/02/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03221413
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 1, 2016
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Single (Participant). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Italy
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Alessandra Del Felice, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Padua, Italy
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  PD: diagnosis of idiopathic PD within the last 5 years (UK Brain Bank criteria);&#x0D;&lt;br&gt;             stable dose of antiparkinson therapy for at least 4 weeks; total off-medication motor&#x0D;&lt;br&gt;             Hoen and Yahr 1-2.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  NP: stable chronic pain for at least the preceding six months; score greater than or&#x0D;&lt;br&gt;             equal to 3 (0 no pain, 10 worst pain) on the visual analog scale (VAS) for pain&#x0D;&lt;br&gt;             perception during the last month before start of stimulation; refractoriness to drugs&#x0D;&lt;br&gt;             for pain relief (pain resistance to at least two of these drugs supplied in adequate&#x0D;&lt;br&gt;             dosages for 6 months).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  PD: concomitant psychiatric disorder; benzodiazepine treatment; Mini Mental State&#x0D;&lt;br&gt;             Examination (MMSE) &lt;26&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  NP: clinically significant or unstable medical or psychiatric disorder, history of&#x0D;&lt;br&gt;             substance abuse&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Pain
    </Condition>
    <Intervention>Device: transcranial alternating current stimulation (tACS)
    </Intervention>
    <Primary_outcome>Proportion of people displaying fast brain oscillatory activity [measured as electroencephalographic (EEG) beta band prevalence];Proportion of people dispalying slow brain oscillatory activity [measured as electroencephalographic (EEG) theta band prevalence];Improvement = 30% of the total off-medication on a motor performance scale (Unified Parkinson's Disease Rating Scale,part III);Pain reduction, measured with a specific scale (NPQ-Neuropathic Pain Questionnaire), as a reduction of at least 4 points
    </Primary_outcome>
    <Secondary_outcome>Modifications of frequencies of oscillatory brain activity, measured as spectral power modifications (prevalence of electroencefalographic frequencies) between T0 and T1 and T1 and T2;Neuropsychological testing: improvement between T0 and T1 and T1 and T2.;Mean change in visual analogue scale (VAS) for pain;Mean change in Short Form (36) Health Survey for NP
    </Secondary_outcome>
    <Secondary_ID>UPadova
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>03/02/2024 23:28:02</Export_date>
    <Internal_Number>11330761
    </Internal_Number>
    <TrialID>NCT02346409
    </TrialID>
    <Last_Refreshed_on>7 September 2021
    </Last_Refreshed_on>
    <Public_title>Cerebello-thalamo-cortical Coupling in Essential Tremor
    </Public_title>
    <Scientific_title>Cerebello-thalamo-cortical Coupling in Essential Tremor: Effects of High Frequency tACS of the Cerebellum
    </Scientific_title>
    <Acronym>CERESTIM
    </Acronym>
    <Primary_sponsor>Institut National de la Santé Et de la Recherche Médicale, France
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20150105
    </Date_registration3>
    <Date_registration>05/01/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02346409
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 4, 2015
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>France
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  age below 75 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  diagnosis of essential tremor according to the criteria of the Tremor Investigation&#x0D;&lt;br&gt;             Group and the Consensus statement of the Movement Disorder Society Group (ref)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  health insurance&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  signed informed written consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  other neurological disorders&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  medications that interact with or influence brain excitability&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  significant brain lesions detected in MRI&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Essential Tremor
    </Condition>
    <Intervention>Device: tACS of the cerebellum
    </Intervention>
    <Primary_outcome>The neuronal activity in the cerebello-thalamo-cortical pathway
    </Primary_outcome>
    <Secondary_ID>2014-A01393-44;C14-44
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>
</Trials_downloaded_from_ICTRP>